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Abstract
Objectives: Endothelial injury during a surgical intervention can significantly affect the 
functional status of the vein. The endothelial layer plays a vital role in the long saphenous 
vein for ensuring smooth blood flow and the prevention of vasoconstriction and thrombi 
formation within the blood vessels. There are few histological studies comparing the 
different vein harvesting techniques that have studied endothelial layer integrity using 
CD31 and CD34 on human long saphenous veins. 
Methods: Non-distended vein samples measuring 1cm were obtained from ten 
consecutive traditional open vein harvesting patients and were automatically processed 
and stained using immunohistochemistry for CD31 and CD34. The colour, intensity and 
distribution of the staining on the tissues was scored blindly by five independent 
scientists and an expert histopathologist for this study. 
Results: The CD34 antibody demonstrated greater colour (p<0.007), intensity (p<0.019) 
and distribution (p<0.007) compared to CD31. 
Conclusion: Our study indicates that CD34 provides a more reliable endothelial marker 
in the long saphenous vein than CD31. The results of this study can be translate into 
other immunohistochemistry studies looking at the quality of the endothelium on the 
vein in cardiac and vascular surgical studies. 
Introduction
Coronary artery bypass surgery (CABG) is the most commonly performed procedure 
in cardiac surgery. This method involves bypassing blocked coronary arteries using 
arterial and venous conduits. Despite the use of arterial conduits providing improved 
long term graft patency, venous conduits such as the long saphenous vein are still widely 
used in multiple bypass surgery due to its long length and easy availability. However, 
donor leg wound complications are among the most common post-surgical problems, 
which may occur in 5% to 44% of cases [1]. Minimally invasive vein harvesting methods 
have been developed to reduce the risk of wound complications and post-operative 
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morbidity. However, these techniques have been associated 
with greater risk of damaging the vein layers, particularly of 
disrupting the endothelium, during surgery. If this occurs, 
platelets become aggregated and induce endothelial 
denudation, promoting intimal proliferation and hyperplasia, 
leading to graft occlusion, which may subsequently result in 
poor long term graft patency [2].
Previous studies have focused on endothelial damage 
occurring during harvesting of the long saphenous vein, 
predominantly via assessment of CD31 expression. CD31 is a 
130-kDa transmembrane glycoprotein, which demonstrates 
strong homogeneous expression in all human pulmonary 
endothelial cells but is also expressed to a lesser extent on 
platelets and some leukocyte subsets [3]. CD34 has also been 
used as a marker of endothelial cells. However, a systematic 
comparison of the quality of these markers would be 
beneficial, especially considering that the molecular and 
functional characteristics of endothelial cells can vary on the 
vascular tree between the different vessels around the body 
[4]. The 110-kDa transmembrane glycoprotein CD34 
demonstrates a more heterogeneous expression and is 
particularly found on endothelial cells of: capillaries, arteries, 
veins, arterioles and venules [5]. Additional markers expressed 
on endothelial cells, such as von Willebrand Factor (vWF) and 
Fli1, have been utilised previously for the identification and 
detection of these cells. The glycoprotein vWF has important 
roles in platelet adhesion following injury, and is expressed on 
endothelial cells in a range of settings. However, vWF has 
been previously demonstrated to have weak expression on 
capillary endothelium and its use may be complicated 
subendothelial expression in certain tissues. Fli1 is consistently 
expressed by endothelial cells in a range of tissues, however it 
is also present within the nucleus of haematopoietic cells, 
especially lymphocytes and is a useful marker for diagnostic 
evaluation and detection of vascular tumours. This study 
evaluated only the use of CD31 and CD34 for assessment of 
endothelial integrity on the long saphenous vein due to the 
nature of their expression patterns.
Immunohistochemistry (IHC) remains the gold standard 
for studying the morphological status of the vein. Although 
previous studies have used IHC to score endothelial integrity, 
none have directly compared the quality of CD31 or CD34 
staining following vein harvesting for CABG surgery. This is 
the first study to compare the difference in colour, intensity 
and distribution of CD31 and CD34 expression on long 
saphenous vein sections with the purpose of identifying a 
standard marker for future IHC for use in assessing endothelial 
integrity.
Methods
Sample collection
An overview of the experimental design for this study is 
included in figure 1. Ethical approval was provided by the 
Greater Manchester North East - National Research Ethics 
Committee (NREC) as part of the vein integrity and clinical 
outcomes (VICO) randomised controlled trial. The VICO trial is 
designed to assess the direct relationship between endothelial 
damage and clinical outcomes. Samples of proximal long 
saphenous veins were collected from the lower leg using the 
open vein harvesting technique from ten consecutive patients. 
Vein conduits retrieved by minimally invasive vein harvesting 
techniques were not included in this study to ensure a reliable 
sample was retrieved with intact endothelium. Vein samples 
that were not surgically distended were utilised in this study 
to provide a reliable result indicative of viable endothelium in 
the long saphenous vein. Samples were cut into approximately 
1cm sections and placed into a solution of 4% formalin in 
distilled water (pH 7.4). Samples were processed using the 
standard operating procedures of the Histopathology 
Laboratory at UHSM. Briefly, formalin fixed samples were 
paraffin embedded, then cut into 4 µm-thin sections, dewaxed 
and rehydrated in graded alcohols. Endogenous peroxidase 
activity was quenched by incubation in a 0.3% hydrogen 
peroxide aqueous solution for 15 minutes at room 
temperature. The heat-induced epitope retrieval method by 
means of pressure cooker was used for antigen retrieval of 
vein cross sections.
Figure 1: Experimental design to compare endothelial markers 
CD31 and CD34
The efficacy of anti-CD31 and anti-CD34 antibodies 
(Dako, Cambridgeshire, UK) to stain the saphenous vein 
endothelium was compared following automated tissue 
immunohistochemistry using both antibodies at a 1:30 
dilution in DAKO™ antibody diluent (Dako, Cambridgeshire, 
UK) according to manufacturer’s protocol. Detection was 
performed using the ImmPress HRP universal antibody 
polymer detection kit (Vector Laboratories, UK) and the 
ImmPact DAB peroxidase (HRP) substrate (Vector Laboratories, 
UK) according to manufacturer’s protocol. Haematoxylin and 
eosin staining was performed for the evaluation of the 
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saphenous vein, as a method for counterstaining (see figure 
2).
Figure 2: The figure 2 demonstrates that the Haematoxylin and 
eosin stained long saphenous vein as a basic control stain before 
staining with the endothelial CD34 and CD31 stain.
Each slide was allocated a random number before any 
assessors assigned a score. The slides were imaged using 
Pannoramic 250™ slide scanner at The University of 
Manchester. This machine has a special high-NA Carl Zeiss™ 
optic lens to achieve maximum resolution of up to 0.16 µm 
per pixel image. Samples were scored by five blinded, 
independent and fully trained assessors by using Pannoramic 
Viewer™ software for efficient image viewing, annotation and 
archiving purposes. All the scores were verified by a UHSM 
Consultant Histopathologist. None of these assessors were 
involved at any stage of this research project. The slides were 
assessed for endothelial integrity (inter assessor variability was 
<15%). Slides were scored based on the colour, intensity and 
staining distribution of CD31 and CD34 using the following 
validated scoring system: “1” neg-none, “2/+” mild, “3/++” 
moderate and “4/+++” intense [4, 6].
Statistical analysis
All data was expressed as percentages, with differences 
between the two sets of results determined using the Chi-
square test for categorical variables. A p-value of <0.05 was 
considered statistically significant. SPSS 19.0 software was 
used for all calculations.
Results
Consecutive saphenous vein sections were stained using 
anti-CD31 and anti-CD34 antibodies. A significantly different 
pattern of expression was found in terms of colour, intensity 
and distribution as follows: 
Colour
The relative colour of CD34 expression on veins was found 
to be more distinct than that of CD31 (80% negligible and 
20% mild colour vs. 60% moderate and 40% strong colour 
distinctiveness for CD34, p=0.019, see figures 3a and 3b). 
Figure 3: (A) CD31 negative colour expression on the cross section 
of the long saphenous vein. (B) CD34 positive colour expression on 
the cross section on the long saphenous vein. (C) CD31 mild 
intensity on the cross sectioned vein. (D) CD34 severe intensity on 
the cross sectioned vein. Pictures A-C magnified: 500 µm and D: 
200 µm.
Intensity
Endothelial cell staining was found to be significantly 
more intense with the use of anti-CD34 antibody, compared 
to the mild staining of CD31 (100% mild staining for CD31 vs. 
20% mild, 40% moderate and 20% strong staining for CD34, 
p=0.019, see figures 3c and 3d). 
Distribution
staining was more widely distributed across the tissue 
compared to CD31, with improved coverage of endothelial 
cells (100% negligible staining for CD31 vs. 40% mild and 60% 
moderate distribution of the stain for CD34, p=0.007). The 
CD34 stain was uniformly distributed along the endothelial 
layer of the saphenous vein. In addition, small capillary vessels 
on the adventitial layer were also effectively stained. In 
contrast, CD31 staining using anti-CD31 was found to be 
irregular along the endothelial layer. 
Discussion
This study aims to compare the use of CD31 and CD34 as 
markers of endothelium on human long saphenous vein. Our 
findings indicate that CD34 stains in a more intense and 
regular manner, including the endothelium of small arterioles 
and venules located in the tunica intima, compared to CD31. 
Modern bioimaging techniques represent a fundamental area 
for evaluation of tissue samples at a cellular level, yet highly 
optimised staining is required for reliable scoring. This is 
particularly true for large scale studies when significant 
numbers of samples need to be assessed as high throughput 
automated methods can be utilised where bright and distinct 
staining is present. 
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The majority of studies assessing endothelial integrity have 
employed CD31 as the key marker, which is expressed on ~90% 
of endothelial tumours [7], ~90% of vascular tumours and 
sinusoids of the spleen [8]. CD31 is also strongly expressed on 
the surface of circulating platelets, monocytes, neutrophils and 
intracellular junctions, making interpretation difficult [3]. Its 
frequent use in analogous studies, without evidence of 
systematic comparison with other markers, led to its acceptance 
as the best single marker for this purpose. In contrast, CD34 is 
assumed to play a major role in the formation of endothelial 
adherence junctions, which are the key components of 
angiogenesis [9, 10]. It is also present on lympho-haematopoietic 
stem and progenitor cells, leukemic cells and embryonic 
fibroblasts. In routine clinical practice, this marker is used for 
leukaemia diagnosis using immunohistochemistry and for the 
purification of immunological stem cells for clinical 
transplantation [11, 12]. Most of these studies focused on 
comparing these markers on a macro rather than a microvascular 
level, which could pose important biological and physiological 
differences. In addition, there is limited evidence comparing 
CD31 and CD34 in human long saphenous vein.
Further knowledge regarding the expression pattern of 
specific endothelial phenotypes on the vascular tree is 
important to evaluate the effectiveness of these markers. 
Although previous studies did not perform a comparison 
between CD31 and CD34 in human long saphenous vein, the 
results of our study suggest that CD34 is a superior marker to 
CD31 in determining the presence of endothelial cells on the 
vessel luminal wall.
In conclusion, the use of CD34 provides a stronger and 
more distinct staining pattern for endothelium in human long 
saphenous vein samples when compared to CD31. This study 
provides novel evidence regarding the use of these markers 
which can have important clinical utility, such as when used as 
indicators of endothelial denudation following harvesting for 
coronary artery bypass surgery.
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